Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial

Area of Science:

• Immunology
• Allergy and Immunology
• Clinical Medicine

Background:

• The jack jumper ant (Myrmecia pilosula) is a primary cause of ant venom anaphylaxis in Australia.
• Anaphylaxis from ant stings poses a significant public health concern in affected regions.

Purpose of the Study:

• To evaluate the efficacy of Myrmecia pilosula venom immunotherapy (VIT) in preventing severe sting anaphylaxis.
• To assess the safety and effectiveness of VIT in otherwise healthy adults with M. pilosula venom allergy.

Main Methods:

• A double-blind, placebo-controlled crossover trial was conducted.
• Participants received either M. pilosula VIT or a placebo, following a standardized desensitization regimen.
• The primary outcome was the incidence of systemic reactions after a controlled sting challenge.

Main Results:

• None of the 23 participants receiving VIT experienced severe systemic reactions to sting challenges, compared to 72% (21/29) in the placebo group (p<0.0001).
• Systemic reactions during VIT occurred in 34% (22/64) of participants, with two cases of hypotension.
• Following crossover, the VIT group showed a low reaction rate (1/26) to sting challenges.

Conclusions:

• Myrmecia pilosula venom immunotherapy is highly effective in preventing anaphylaxis in motivated, highly allergic adults.
• VIT should be administered under strict medical supervision with immediate access to resuscitation facilities due to potential systemic reactions.